Scientists have created at least five new experimental substances - based on a tiny protein found in cone snail venom - that could lead to the development of safe and effective oral medications for treatment of chronic nerve pain.
The substances could potentially be stronger than morphine, with fewer side effects and lower risk of abuse. researchers said.
"This is an important incremental step that could serve as the blueprint for the development of a whole new class of drugs capable of relieving one of the most severe forms of chronic pain that is currently very difficult to treat," said David Craik from the University of Queensland.
In contrast, chronic neuropathic pain kicks in when the nervous system itself is damaged.
This type of pain - which is often triggered by diabetes, multiple sclerosis and other diseases - can last for months, years or even decades.
Current treatments for chronic neuropathic pain have serious side effects and provide relief to only about one in every three patients, Craik said.
Cone snails are marine animals that use venom to paralyse their prey.
However, so far only one conotoxin-derived medication has been approved for human use. This drug, ziconotide, has one big drawback: It has to be infused directly into the lower part of the spinal cord - a clearly invasive procedure.
The team is working to develop a conotoxin-based drug that can be taken orally, which would be much more practical for patients.
They found a way to modify conotoxin peptides so they formed circular chains of amino acids. As a result, the modified peptides - which are essentially tied into a loop - are extremely stable and resistant to enzymes in the body.
Scientists concluded that this prototype drug was about 100 times more potent than morphine or gabapentin, the two drugs that are considered the "gold standard" treatments for chronic nerve pain.
Addiction is less of a concern because conotoxins act on different receptors in the brain than morphine and other opiate drugs, Craik said.
The finding was presented at the National Meeting & Exposition of the American Chemical Society (ACS) in Dallas.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
